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Development of a mathematical model for batch crystallization of fesoterodine fumarate, an active pharmaceutical ingredient, 
in 2-butanone is presented. The model is based on population, mass and energy balances, and takes into account nucleation, 
crystal growth and agglomeration. Equilibrium solubility was determined experimentally by ATR-FTIR spectroscopy. Kinetic 
parameters were determined by fitting of experimental and simulated concentration curves and particle size distributions for 
six crystallization experiments, performed under different operating conditions. The model was validated and the results show 
good agreement with experimental data.  
 
 




Crystallization is the most important separation and 
purification operation in the pharmaceutical industry for 
the production of chemical intermediates and active 
pharmaceutical ingredients (APIs). The majority of 
crystallizations in pharmaceutical industry are batch 
crystallizations from solutions, where supersaturation is 
achieved either by cooling and/or addition of an 
antisolvent. The operating conditions of a crystallization 
process determine the physicochemical properties of the 
solid crystal product, such as particle size distribution, 
polymorphic form, crystal morphology and purity. These 
can have a profound impact on downstream processing 
and most importantly on stability and therapeutic 
properties of the final formulation. In order to ensure safety 
and efficacy of pharmaceuticals, the regulatory agencies 
have set strict standards, which include control and 
consistency of solid phase properties through 
crystallization. This requires in-depth understanding of the 
fundamental crystallization phenomena (nucleation, 
crystal growth, agglomeration etc.), as well as the impact of 
crystallization equipment and the critical issue of scale-up. 
Mathematical modelling has been acknowledged as a 
valuable tool for design, optimization and control of  
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crystallization processes. However, due to the complexity 
of the process, crystallization modelling has not yet been 




Fesoterodine fumarate is a muscarinic receptor antagonist 
that is used for the treatment of overactive bladder 
syndrome. It exists in several polymorphic forms (I, A, B, 
C), but it is possible to obtain pure form I crystals by cooling 
crystallization using 2-butanone as the solvent.
4
 According 
to the best of our knowledge, the solubility data, 
mechanism and kinetics of fesoterodine fumarate 
formation by crystallization have not yet been described in 
scientific literature. 
The purpose of our work was to determine the 
thermodynamic and kinetic parameters of fesoterodine 
fumarate cooling crystallization in 2-butanone. A 
mathematical model of the process was developed, which 
was supported by experimental determination of solubility 
equilibrium using calibrated Attenuated total reflectance 
Fourier-transform infrared (ATR-FTIR) spectroscopy and six 
crystallization experiments, performed under five different 
operating conditions. The model was validated by a 
comparison of the simulated results with experimental 




Fesoterodine fumarate and 2-butanone were donated 
from Lek d.
 
d. All experiments were performed in 2-L batch 
reactor AP01-2 with pitched blade turbine impeller (4 
blades), integrated into a RC1e reactor system (Mettler 
Toledo, Switzerland) with DW Therm silicone oil (DWS Dr. 
Wilharm Synthesetechnik, Germany) as the cooling 
medium in the jacket. Solution concentration 
measurements were performed using in-line ATR-FTIR 
spectroscopy ReactIR 45m (Mettler Toledo) with SiComp
TM
 
sensor and fibre probe. Infrared spectra were recorded 
between 2800 and 650 cm
−1
 with resolution of 4 cm
−1
 
and averaged over 128 scans. iC IR 7.0 software (Mettler 
Toledo) was used for ReactIR 45 m calibration and solution 
concentration calculation. Particle size distributions of final 
crystalline products were determined by optical 
microscope Olympus BX51 (Olympus, Japan) coupled with 
Stream Motion image analysis software (Olympus). 
Mathematical modelling was performed in Matlab 
(Mathworks, MA, USA).  
 
Crystallization process may be described by three time-
dependent balances: population, energy and mass 
balances. Population balance equation is a partial integro-
differential equation that describes the evolution of crystal 
size distribution during the process. If numerically solved 
by Abbas discretization technique,
5
 it can be written for r 
size classes as a system of ordinary differential equations 
(Eq. (1) for i = 1, Eq. (2) for i = 2, …, r – 1 and Eq. (3) for 
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size class width for class i [m], and Ri crystal agglomeration 





Nucleation (Eq. (4)) takes place in the smallest size class. 
















], mcr total mass 
of crystals [kg], Vsol solution volume [m
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 of solvent], and n nucleation order  
[-]. 
Crystal growth (Eq. (5)) can be perceived as a two-step 
mechanism with mass transfer from bulk solution to solid-
liquid interface and solute integration from the interface 
into the crystal lattice. No crystal growth takes place from 
the largest size class r. A quantitative measure of mass 
transfer from the bulk solution to the interface is solid-




]. It can be 
calculated by Frossling equation (Eq. (6)).  
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(6) 
ka and kv represent crystal area and volume factors [-], ρsol 


















], g crystal 




], Li crystal 
size on the boundary between classes i and I + 1 [m], Rep,i 
Reynolds number of crystals in class i [-], and Sc Schmidt 
number [-]. 
Agglomeration of crystals of classes j and k (k ≥ j) into 
crystals of class l can be described by Eq. (7) using the 
approach of Marchal.
6
 Crystals from the largest size class 
i = r do not agglomerate, however, they may be formed 
by agglomeration of smaller crystals. Laminar collision was 
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where m is agglomeration index [-], kR crystal 




], Si average size of 









], and δi,j Kronecker 
delta [-]. 
Temperature change in the reactor during the 
crystallization process is described by Eq. (8). The enthalpy 







] is calculated by Eq. (9). Reactor-







] are determined by standard correlations 
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Tr and Tj represent reactor and jacket temperatures [°C], A 
area of reactor wall available for heat transfer [m
2
], mr total 
mass of crystallization mixture [kg], cp,r specific heat 






], x reactor wall 




Bulk solution concentration at a certain time t during the 
process is calculated by subtracting the mass of the formed 
crystals mcr at that time from the mass of initially dissolved 
solute m0 [kg] and mass of added seed crystals mseed [kg], 
divided by mass of solvent msol [kg] (Eq. (10)). Total mass of 
the crystals is calculated as the sum of masses of crystals 
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Table 1   
 
– List of crystallization experiments with corresponding operating conditions.  
   d50 is number-based crystal size distribution median. 
Tablica 1 – Popis eksperimenata kristalizacije s odgovarajućim radnim uvjetima.  
d50 je brojčani medijan raspodjele veličine kristala. 












Amount of seed 
Količina cjepiva 











1 2.5 3.7 5.0 35.0 300 
2 2.5 3.7 10.0 35.0 300 
3 2.5 5.8 5.0 35.0 300 
4 2.5 5.8 5.0 35.0 400 
5 2.5 5.8 5.0 30.0 300 
6 10.0 5.8 5.0 35.0 300 
7 5.0 8.9 7.5 32.5 350 
ATR-FTIR spectroscopy was calibrated with solutions 




 of solvent at 
temperatures from −10.0 to 40.0 °C (43 combinations). 
Ten spectra were recorded for every combination of 
temperature and concentration, with seven spectra used 
for calibration and three spectra for validation. A 
multivariate calibration model was constructed between 
concentration as dependent variable and spectral data 
and solution temperature as independent variables using 
partial least squares (PLS) regression. All spectral data at 
wavenumbers between 660 and 1850 cm
−1
 were used, 
which means 319 variables were taken into account for 
every spectra (altogether 320 independent variables 
including temperature). Models with different number of 
latent factors were evaluated and the one with 5 latent 





both above 0.99) with the smallest number of factors 
used. 
 
Equilibrium (saturated) concentration was determined 
isothermally at different temperatures from −10.0 to 
40.0 °C. An excess of fesoterodine fumarate was 
suspended in 2-butanone at 40 °C and stirred at 300 rpm 
for 7 h. Temperature was decreased in step of 5.0 °C and 
stirred for 7 h every step. 
 
Six cooling crystallization experiments were conducted for 
determination of kinetic parameters under different 
operating conditions (Table 1; Exp. 1–6) and one 
experiment was conducted for model validation (Exp. 7). 
Fesoterodine fumarate (0.100 kg) was dissolved in 




 of solvent) at 
40.0 °C and the mixture was linearly cooled to −10.0 °C. 
Solution concentration during crystallization was measured 
by ATR-FTIR spectroscopy. Seed crystals were added at the 




were varied: cooling rate, size of seed, amount of seed, 
seeding temperature and stirring rate. When the final 
temperature was reached, the suspension was stirred for 
additional 30 min. The white solid was filtered and dried 
for 20 h at 30 °C in vacuo. 
 
Matlab function fminsearch, based on Nelder-Mead 
simplex method, was used for determination of kinetic 
parameters kN, n, kG, g, and kR through nonlinear regression 
of experimental and simulated concentration curves and 
crystal size distributions.  
 
Equilibrium solubility of fesoterodine fumarate in  
2-butanone in the studied temperature range is shown in 
Fig. 1. For modelling purposes, a 6
th
 degree polynomial 
was fitted to the experimentally determined data. The 


















































Experimentally determined concentration curves show that 
no crystallization occurs prior to seed addition (Fig. 2; left). 
A few degrees below seeding, a profound drop in 
 
concentration to equilibrium solubility is observed, which 
is fastest in Exp. 2, where the largest amount of seed was 
added, and slowest in Exp. 6, where the highest cooling 
rate was used. Final size of particles ranges between 




Fig. 1   – Equilibrium solubility of fesoterodine fumarate in 2-
butanone 





Fig. 2  
 
– Experimental concentration curves and particle size distributions for Exp. 1–6 








Fig. 3   – Validation of particle size distribution and concentration 
curve prediction 




The amount of seed has no profound impact on the final 
particle size distribution, indicating that nucleation and 
agglomeration play an important role in the process. 
However, initial particle size distribution of added seed 
does impact the final product, as larger particles are 
obtained by using seed crystals of larger average size. 
Lower seeding temperature leads to formation of smaller 
crystals due to higher nucleation rate, while higher stirring 
rate leads to larger crystals of the product due to higher rate 
of crystal growth and agglomeration. Higher cooling rate 
leads to formation of smaller particles as higher 
supersaturation and thus nucleation rate is achieved. 
Optimized kinetic parameters of nucleation, crystal growth 
and crystal agglomeration are listed in Table 2.  
Orders of nucleation and crystal growth are larger than 1, 
indicating nonlinear dependence of respective rates on 
supersaturation. 
Nucleation order is larger than crystal growth order, which 
means that, at lower supersaturations, only crystal growth 
takes place. Value of crystal growth constant is lower than 









, depending on particle size), indicating 
that integration is the rate-limiting step. 
The results of model validation are shown in Fig. 3, where 
a good agreement between predicted and experimental 
results is achieved. The model predicts slightly higher initial 
crystal growth rate, which can be seen as faster 
concentration decrease after seeding (Fig. 3; up). The 
predicted final particle size distribution is shifted slightly 
towards smaller particles, compared to experimental 
measurements (Fig. 3; down). It appears that the rate of 
agglomeration, which results in formation of larger 




Table 2   
 
– Optimized kinetic parameters of fesoterodine fumarate crystallization 
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 3.05 6.28 ∙ 10
−8








Mathematical modelling is a useful tool for studying 
crystallization, both in academic and industrial settings. 
Batch crystallization of fesoterodine fumarate in  
2-butanone under different operating conditions can be 
adequately simulated after solubility equilibrium and 
kinetic parameters have been determined 
experimentally. Further work will be dedicated to more 
thorough understanding of fesoterodine fumarate 
crystallization by implementation of other process 
analytical technologies, such as focused beam reflectance 
measurement (FBRM).  
Model could also be improved by taking into account 
additional experimental results for more accurate 
determination of kinetic parameters, such as FBRM chord 
counts and chord length distributions, as well as crystal size 
distributions of sampled crystal slurries during the process. 
In-depth optical microscopy image analysis could help 
differentiate between agglomerates and primary particles, 
and thus enable us to determine more accurate crystal 
agglomeration rate. Additional operating conditions, such 
as temperature cycling and antisolvent addition, as well as 
scale-up, will be studied. 
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U radu je prikazan razvoj matematičkog modela šaržne kristalizacije fezoterodin fumarata, aktivne farmaceutske tvari, u  
2-butanonu. Model se temelji na populacijskoj bilanci te bilanci tvari i energije, a uzima u obzir nukleaciju, rast kristala i 
aglomeraciju. Ravnotežna topljivost određena je eksperimentalno pomoću spektroskopije ATR-FTIR. Kinetički parametri su 
određeni primjenom eksperimentalnih i simuliranih krivulja koncentracije i raspodjele veličine čestica za šest kristalizacijskih 
eksperimenata provedenih pod različitim uvjetima. Model je validiran i rezultati su u skladu s eksperimentalnim podatcima. 
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